Stefano R. Tarantolo
Research Subjects
Research Interests
Stefano R. Tarantolo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Daniel Lydiatt
Department of Otology‐Head and Neck Surgery, University of Nebraska Medical Center, Omaha, Nebraska
1 shared publicationJames R. Neff
Department of Orthopaedic Surgery, University of Nebraska Medical Center, Omaha, Nebraska
1 shared publicationJulia A. Bridge
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
1 shared publicationRandall J. Olsen
Department of Pathology and Laboratory Medicine, Baylor College of Medicine, Houston, Texas, USA
1 shared publicationSabine Naumann
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska
1 shared publicationScott A. Koepsell
1 shared publication
Latest Publications
- 12 September 2005
- Published by Wiley in Head & Neck
- Vol. 27 (10) , 883-892
C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck
Background. Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C‐erb‐B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor. Methods. Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C‐erb‐B2 (HER2/neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH). Results. The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen‐targeted antibody therapy (trastuzumab) was initiated in two patients. Conclusions. These results demonstrate that C‐erb‐B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities. © 2005 Wiley Periodicals, Inc. Head Neck 27: XXX–XXX, 2005
- 12 September 2005
- Published by Wiley in Head & Neck
- Vol. 27 (10) , 883-892
C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck
Background. Synovial sarcoma is a malignant mesenchymal tumor composed of varying proportions of spindle and epithelial cell components. Because of the histologic and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, we hypothesized that the human epithelial growth factor receptor 2 (C‐erb‐B2, also termed HER2/neu) may contribute to the tumor phenotype and provide a new therapeutic target for this soft tissue tumor. Methods. Three head and neck, one chest wall, and seven extremity synovial sarcomas were evaluated for C‐erb‐B2 (HER2/neu) expression by immunohistochemistry, Western immunoblotting, and fluorescence in situ hybridization (FISH). Results. The head and neck cases demonstrated immunohistochemically strong positive staining, whereas tumors from other anatomic locations showed neither positive nor cytoplasmic restricted staining. Antigen‐targeted antibody therapy (trastuzumab) was initiated in two patients. Conclusions. These results demonstrate that C‐erb‐B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities. © 2005 Wiley Periodicals, Inc. Head Neck 27: XXX–XXX, 2005